In some patients infected with Kovid-19, antibody levels are 30,000 to 40,000, but in some people who have received the vaccine, it is less than 50.
Odisha Corona News: Bhubaneswar-based Institute of Life Science (ILS) has said that about 20 percent of people who have received both doses of anti-Covid-19 vaccine in Odisha have failed to develop antibodies against SARS-CoV2 and require a booster dose. can. ILS Director Dr. Ajay Parida informed that so far more than 61.32 lakh people in Odisha have received both doses of anti-Covid-19 vaccine in which more than 10 lakh people are in Bhubaneswar and about 20 percent of them have SARS-CoV2. Antibodies have not been produced against this disease and they may require a booster dose.Also Read – Government employees who do not take a single dose of corona vaccine in this state will be sent on leave, know what is the order
The ILS director said, “Although the antibody level in some patients infected with Kovid-19 is 30,000 to 40,000, it is less than 50 in some people who have received the vaccine. If the antibody level is 60 to 100 then we can say that the person is antibody positive. Also Read – Co-Win has released a new API, now it will be easy to know who got vaccinated and who did not
He said that the effectiveness of the Covishield and Covaccine vaccines is only 70 to 80 percent. He explained that the inability to make antibodies despite taking two doses of the anti-Covid-19 vaccine could be due to individual differences in the genetic sequence. “This fact was revealed through antibody genome sequencing studies,” he said. Also Read – Hospital made a bill of Rs 1.8 crore for the treatment of Corona patient, doctors started shouting after asking for exemption
Dr. Parida said that apart from children and adolescents aged 0 to 18 years, these 20 percent of adults who have taken both doses of the vaccine are also vulnerable to the infection of Kovid-19. They need to be extra careful during a possible third wave of the pandemic. Bhubaneswar-based ILS is part of the Indian SARS-CoV2 Genome Consortium, a network of 28 laboratories spread across the country.